

Vicente Vicente

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4444120/publications.pdf>

Version: 2024-02-01

423
papers

12,014
citations

31902

53
h-index

54797

84
g-index

453
all docs

453
docs citations

453
times ranked

13649
citing authors

#	ARTICLE	IF	CITATIONS
1	Recognition of distinct adhesive sites on fibrinogen by related integrins on platelets and endothelial cells. <i>Cell</i> , 1989, 58, 945-953.	13.5	337
2	Platelet receptors and signaling in the dynamics of thrombus formation. <i>Haematologica</i> , 2009, 94, 700-711.	1.7	337
3	Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. <i>Blood</i> , 2010, 116, 1205-1210.	0.6	202
4	Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. <i>Blood</i> , 2012, 119, 1363-1369.	0.6	198
5	Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. <i>Breast Cancer Research</i> , 2014, 16, 488.	2.2	197
6	Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2013, 110, 1189-1198.	1.8	182
7	Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm. <i>Nature Genetics</i> , 2010, 42, 692-697.	9.4	181
8	Predictive Value of the HAS-BLED and ATRIA Bleeding Scores for the Risk of Serious Bleeding in a "Real-World" Population With Atrial Fibrillation Receiving Anticoagulant Therapy. <i>Chest</i> , 2013, 143, 179-184.	0.4	176
9	The HAS-BLED Score Has Better Prediction Accuracy for Major Bleeding Than CHADS2 or CHA2DS2-VASc Scores in Anticoagulated Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2199-2204.	1.2	171
10	Polymorphisms of Platelet Membrane Glycoprotein Ib "Associated With Arterial Thrombotic Disease. <i>Blood</i> , 1998, 92, 2771-2776.	0.6	168
11	Flavonoids inhibit platelet function through binding to the thromboxane A2 receptor. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 369-376.	1.9	168
12	Cytotoxicity and Antiproliferative Activities of Several Phenolic Compounds Against Three Melanocytes Cell Lines: Relationship Between Structure and Activity. <i>Nutrition and Cancer</i> , 2004, 49, 191-199.	0.9	141
13	Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. <i>American Journal of Hematology</i> , 1991, 36, 249-254.	2.0	126
14	Rosmarinic acid, a photo-protective agent against UV and other ionizing radiations. <i>Food and Chemical Toxicology</i> , 2009, 47, 386-392.	1.8	123
15	Relation of the HAS-BLED Bleeding Risk Score to Major Bleeding, Cardiovascular Events, and Mortality in Anticoagulated Patients With Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 312-318.	2.1	123
16	Plasma von Willebrand Factor Levels Are an Independent Risk Factor for Adverse Events Including Mortality and Major Bleeding in Anticoagulated Atrial Fibrillation Patients. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2496-2504.	1.2	121
17	SAMe-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial Fibrillation. <i>American Journal of Medicine</i> , 2014, 127, 1083-1088.	0.6	112
18	Renal Impairment in a "Real-Life" Cohort of Anticoagulated Patients With Atrial Fibrillation (Implications for Thromboembolism and Bleeding). <i>American Journal of Cardiology</i> , 2013, 111, 1159-1164.	0.7	110

#	ARTICLE	IF	CITATIONS
19	Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. <i>Blood</i> , 2007, 109, 4258-4263.	0.6	104
20	Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?. <i>Thrombosis and Haemostasis</i> , 2013, 109, 956-960.	1.8	102
21	Identification of miRNAs as potential modulators of tissue factor expression in patients with systemic lupus erythematosus and antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1985-1992.	1.9	98
22	High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1500-1507.	1.9	97
23	Introducing high-throughput sequencing into mainstream genetic diagnosis practice in inherited platelet disorders. <i>Haematologica</i> , 2018, 103, 148-162.	1.7	96
24	Contribution of Factor VII Genotype to Activated FVII Levels. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 2548-2553.	1.1	94
25	The venous thrombosis risk factor 20210 A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease. <i>British Journal of Haematology</i> , 1997, 99, 304-307.	1.2	92
26	Nonsense mutation in the glycoprotein Ib alpha coding sequence associated with Bernard-Soulier syndrome.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990, 87, 2026-2030.	3.3	91
27	A multimarker risk stratification approach to non-ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro-BNP and fibrin D-dimer levels. <i>Journal of Internal Medicine</i> , 2007, 262, 651-658.	2.7	87
28	Role of Lipopolysaccharide and Cecal Ligation and Puncture on Blood Coagulation and Inflammation in Sensitive and Resistant Mice Models. <i>American Journal of Pathology</i> , 2005, 166, 1089-1098.	1.9	81
29	Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. <i>American Heart Journal</i> , 2008, 156, 85-91.	1.2	80
30	Polymorphisms of clotting factors modify the risk for primary intracranial hemorrhage. <i>Blood</i> , 2001, 97, 2979-2982.	0.6	79
31	Disruption of GIP/GIPR Axis in Human Adipose Tissue Is Linked to Obesity and Insulin Resistance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E908-E919.	1.8	79
32	Determination of plasma protein C inhibitor and of two activated protein C-inhibitor complexes in normals and in patients with intravascular coagulation and thrombotic disease. <i>Thrombosis Research</i> , 1990, 59, 593-608.	0.8	78
33	Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE registry. <i>Thrombosis Research</i> , 2009, 124, 174-177.	0.8	78
34	The genetics of antithrombin. <i>Thrombosis Research</i> , 2018, 169, 23-29.	0.8	77
35	Effects of several flavonoids on the growth of B16F10 and SK-MEL-1 melanoma cell lines : relationship between structure and activity. <i>Melanoma Research</i> , 2002, 12, 99-107.	0.6	76
36	Flavonoids inhibit the platelet TxA2 signalling pathway and antagonize TxA2 receptors (TP) in platelets and smooth muscle cells. <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 133-144.	1.1	76

#	ARTICLE	IF	CITATIONS
37	Apigenin Inhibits Platelet Adhesion and Thrombus Formation and Synergizes with Aspirin in the Suppression of the Arachidonic Acid Pathway. <i>Journal of Agricultural and Food Chemistry</i> , 2008, 56, 2970-2976.	2.4	74
38	Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1448-1454.	1.8	74
39	Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. <i>Blood</i> , 2009, 113, 4977-4979.	0.6	73
40	Novel mutations in RASGRP2, which encodes CalDAG-GEFI, abrogate Rap1 activation, causing platelet dysfunction. <i>Blood</i> , 2016, 128, 1282-1289.	0.6	68
41	Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. <i>Annals of Hematology</i> , 2014, 93, 2037-2043.	0.8	66
42	MiR-146a Regulates Neutrophil Extracellular Trap Formation That Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 892-902.	1.1	66
43	A common polymorphism in the annexin V Kozak sequence (>T) increases translation efficiency and plasma levels of annexin V, and decreases the risk of myocardial infarction in young patients. <i>Blood</i> , 2002, 100, 2081-2086.	0.6	65
44	Supportive management strategies for disseminated intravascular coagulation. <i>Thrombosis and Haemostasis</i> , 2016, 115, 896-904.	1.8	65
45	Prognostic evaluation of febrile neutropenia in apparently stable adult cancer patients. <i>British Journal of Cancer</i> , 2011, 105, 612-617.	2.9	64
46	Beneficial Action of Citrus Flavonoids on Multiple Cancer-Related Biological Pathways. <i>Current Cancer Drug Targets</i> , 2007, 7, 795-809.	0.8	62
47	Variant Bernard-Soulier syndrome type bolzano. A congenital bleeding disorder due to a structural and functional abnormality of the platelet glycoprotein Ib-IX complex.. <i>Journal of Clinical Investigation</i> , 1990, 86, 25-31.	3.9	61
48	A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis. <i>Blood</i> , 2006, 108, 177-183.	0.6	58
49	Angiogenic role of miR-20a in breast cancer. <i>PLoS ONE</i> , 2018, 13, e0194638.	1.1	58
50	Adjuvant therapy with bempiparin in patients with limited-stage small cell lung cancer: Results from the ABEL study. <i>Thrombosis Research</i> , 2013, 132, 666-670.	0.8	57
51	Towards the targeted management of Chediak-Higashi syndrome. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 132.	1.2	57
52	Long-term bleeding risk prediction in "real world"™ patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1848-1858.	1.8	56
53	Loss of high-affinity thrombin receptors during platelet concentrate storage impairs the reactivity of platelets to thrombin. <i>Transfusion</i> , 1997, 37, 368-375.	0.8	54
54	Role of Fibrinogen Levels and Factor XIII V34L Polymorphism in Thrombolytic Therapy in Stroke Patients. <i>Stroke</i> , 2006, 37, 2288-2293.	1.0	54

#	ARTICLE	IF	CITATIONS
55	Protein Z/Z-dependent protease inhibitor (PZ/ZPI) anticoagulant system and thrombosis. British Journal of Haematology, 2007, 137, 99-108.	1.2	54
56	Mutations in the shutter region of antithrombin result in formation of disulfide-linked dimers and severe venous thrombosis. Journal of Thrombosis and Haemostasis, 2004, 2, 931-939.	1.9	53
57	Association of Anthracycline-Related Cardiac Histological Lesions With NADPH Oxidase Functional Polymorphisms. Oncologist, 2013, 18, 446-453.	1.9	53
58	Biallelic Mutations in KDSR Disrupt Ceramide Synthesis and Result in a Spectrum of Keratinization Disorders Associated with Thrombocytopenia. Journal of Investigative Dermatology, 2017, 137, 2344-2353.	0.3	53
59	Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EIPHANY study. European Respiratory Journal, 2017, 49, 1600282.	3.1	52
60	The SAME-TT2R2 Score Predicts Poor Anticoagulation Control in AF Patients: A Prospective "Real-world" Inception Cohort Study. American Journal of Medicine, 2015, 128, 1237-1243.	0.6	51
61	Peritoneal fluid modifies the microRNA expression profile in endometrial and endometriotic cells from women with endometriosis. Human Reproduction, 2015, 30, 2292-2302.	0.4	51
62	Hereditary thrombophilia: identification of nonsense and missense mutations in the protein C gene.. Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 2829-2832.	3.3	50
63	Clinical and genetic determinants of anthracycline-induced cardiac iron accumulation. International Journal of Cardiology, 2012, 154, 282-286.	0.8	49
64	Predictive value of peripheral blood lymphocyte count in breast cancer patients treated with primary chemotherapy. Breast, 2012, 21, 468-474.	0.9	49
65	Refining Stroke and Bleeding Prediction in Atrial Fibrillation by Adding Consecutive Biomarkers to Clinical Risk Scores. Stroke, 2019, 50, 1372-1379.	1.0	48
66	l-Asparaginase-Induced Antithrombin Type I Deficiency. American Journal of Pathology, 2006, 169, 142-153.	1.9	47
67	In Silico Discovery of a Compound with Nanomolar Affinity to Antithrombin Causing Partial Activation and Increased Heparin Affinity. Journal of Medicinal Chemistry, 2012, 55, 6403-6412.	2.9	47
68	Evaluation of four rapid methods for hemoglobin screening of whole blood donors in mobile collection settings. Transfusion and Apheresis Science, 2007, 36, 235-242.	0.5	46
69	Thromboxane A ₂ Receptor Antagonism by Flavonoids: Structure-Activity Relationships. Journal of Agricultural and Food Chemistry, 2009, 57, 1589-1594.	2.4	46
70	Multirefractory primary immune thrombocytopenia; targeting the decreased sialic acid content. Platelets, 2019, 30, 743-751.	1.1	45
71	Differential effects of quercetin, apigenin and genistein on signalling pathways of protease-activated receptors PAR ₁ and PAR ₄ in platelets. British Journal of Pharmacology, 2009, 158, 1548-1556.	2.7	44
72	Inherited Platelet Disorders: An Updated Overview. International Journal of Molecular Sciences, 2021, 22, 4521.	1.8	44

#	ARTICLE	IF	CITATIONS
73	Homozygous Deficiency of Heparin Cofactor II. <i>Circulation</i> , 2004, 110, 1303-1307.	1.6	43
74	Quantification of Circulating Activated Protein C in Human Plasma by Immunoassays - Enzyme Levels are Proportional to Total Protein C Levels. <i>Thrombosis and Haemostasis</i> , 1996, 75, 056-061.	1.8	43
75	Long-Term Stroke Risk Prediction in Patients With Atrial Fibrillation: Comparison of the ABC-Stroke and CHA ₂ DS ₂ -VASc Scores. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	42
76	The number of platelet glycoprotein Ia molecules is associated with the genetically linked 807 C/T and HPA-5 polymorphisms. <i>Transfusion</i> , 1999, 39, 372-378.	0.8	41
77	Valor predictivo de la escala CHA ₂ DS ₂ -VASc en pacientes con fibrilación auricular de alto riesgo embólico en tratamiento anticoagulante. <i>Revista Espanola De Cardiología</i> , 2012, 65, 627-633.	0.6	41
78	Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1200-1207.	1.8	41
79	Predicting serious complications in patients with cancer and pulmonary embolism using decision tree modelling: the EPIPHANY Index. <i>British Journal of Cancer</i> , 2017, 116, 994-1001.	2.9	40
80	Platelet septin complexes form rings and associate with the microtubular network. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1388-1395.	1.9	39
81	Functional consequences of the prothrombotic SERPINC1 rs2227589 polymorphism on antithrombin levels. <i>Haematologica</i> , 2009, 94, 589-592.	1.7	39
82	Usefulness of N-Terminal Pro-B-Type Natriuretic Peptide Levels for Stroke Risk Prediction in Anticoagulated Patients With Atrial Fibrillation. <i>Stroke</i> , 2014, 45, 696-701.	1.0	39
83	miR-146a is a pivotal regulator of neutrophil extracellular trap formation promoting thrombosis. <i>Haematologica</i> , 2021, 106, 1636-1646.	1.7	39
84	Detection of Factor V Leiden from a Drop of Blood by PCR-SSCP. <i>Thrombosis and Haemostasis</i> , 1996, 76, 735-737.	1.8	39
85	Polymorphisms of P-selectin glycoprotein ligand-1 are associated with neutrophil-platelet adhesion and with ischaemic cerebrovascular disease. <i>British Journal of Haematology</i> , 2001, 115, 969-976.	1.2	38
86	The association of the α 1-tubulin Q43P polymorphism with intracerebral hemorrhage in men. <i>Haematologica</i> , 2007, 92, 513-518.	1.7	38
87	Hypoglycosylation is a common finding in antithrombin deficiency in the absence of a SERPINC1 gene defect. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1549-1560.	1.9	38
88	Coagulation Abnormalities in Patients with Mediterranean Spotted Fever. <i>Journal of Infectious Diseases</i> , 1986, 153, 128-131.	1.9	37
89	HPA-1 genotype in arterial thrombosis???role of HPA-1b polymorphism in platelet function. <i>Blood Coagulation and Fibrinolysis</i> , 1997, 8, 284-290.	0.5	37
90	Genetic polymorphisms of factor VII are not associated with arterial thrombosis. <i>Blood Coagulation and Fibrinolysis</i> , 1998, 9, 267-272.	0.5	37

#	ARTICLE	IF	CITATIONS
91	Plasma angiogenin levels in acute coronary syndromes: implications for prognosis. <i>European Heart Journal</i> , 2007, 28, 3006-3011.	1.0	37
92	Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis. <i>Thrombosis and Haemostasis</i> , 2009, 101, 483-486.	1.8	37
93	L718P mutation in the membrane-proximal cytoplasmic tail of $\text{A}\beta$ promotes abnormal $\text{A}\beta$ clustering and lipid microdomain coalescence, and associates with a thrombasthenia-like phenotype. <i>Haematologica</i> , 2010, 95, 1158-1166.	1.7	37
94	Amelioration of the severity of heparin-binding antithrombin mutations by posttranslational mosaicism. <i>Blood</i> , 2012, 120, 900-904.	0.6	37
95	Comprehensive comparison of neonate and adult human platelet transcriptomes. <i>PLoS ONE</i> , 2017, 12, e0183042.	1.1	37
96	Effects of several polyhydroxylated flavonoids on the growth of B16F10 melanoma and Melan-a melanocyte cell lines. <i>Melanoma Research</i> , 2003, 13, 3-9.	0.6	36
97	Factor XIII Val34Leu polymorphism modulates the prothrombotic and inflammatory state associated with atrial fibrillation. <i>Journal of Molecular and Cellular Cardiology</i> , 2004, 37, 699-704.	0.9	36
98	miR-133a Regulates Vitamin K 2,3-Epoxide Reductase Complex Subunit 1 (VKORC1), a Key Protein in the Vitamin K Cycle. <i>Molecular Medicine</i> , 2012, 18, 1466-1472.	1.9	36
99	Prognostic role of MIR146A polymorphisms for cardiovascular events in atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2014, 112, 781-788.	1.8	36
100	Activation of the protein C pathway in acute sepsis. <i>Thrombosis Research</i> , 1995, 79, 83-93.	0.8	35
101	Prothrombin A19911G and G20210A polymorphisms' role in thrombosis. <i>British Journal of Haematology</i> , 2002, 118, 610-614.	1.2	35
102	Treatment of the open abdomen with topical negative pressure therapy: a retrospective study of 46 cases. <i>International Wound Journal</i> , 2011, 8, 274-279.	1.3	35
103	Stability of Glycoproteins Ib/IX and IIb/IIIa during Preparation and Storage of Platelet Concentrates: Detection by Binding Assays with Epitope-Defined Monoclonal Antibodies and Physiological Ligands. <i>Vox Sanguinis</i> , 1994, 67, 166-171.	0.7	34
104	Prospective Randomized Study Comparing the Efficacy of Bioequivalent Doses of glycosylated and nonglycosylated rG-CSF for Mobilizing Peripheral Blood Progenitor Cells. <i>British Journal of Haematology</i> , 1997, 96, 418-420.	1.2	34
105	The effects of radiofrequency on skin: Experimental study. <i>Lasers in Surgery and Medicine</i> , 2008, 40, 76-82.	1.1	34
106	Effect of citrullination on the function and conformation of antithrombin. <i>FEBS Journal</i> , 2009, 276, 6763-6772.	2.2	34
107	Liposoluble antioxidants provide an effective radioprotective barrier. <i>British Journal of Radiology</i> , 2009, 82, 605-609.	1.0	34
108	Antithrombin Murcia (K241E) causing antithrombin deficiency: a possible role for altered glycosylation. <i>Haematologica</i> , 2010, 95, 1358-1365.	1.7	34

#	ARTICLE	IF	CITATIONS
109	Regulation of Coagulation Factor XI Expression by MicroRNAs in the Human Liver. PLoS ONE, 2014, 9, e111713.	1.1	34
110	Antithrombin controls tumor migration, invasion and angiogenesis by inhibition of enteropeptidase. Scientific Reports, 2016, 6, 27544.	1.6	34
111	Normal pregnancy in a patient with a postpartum factor VIII inhibitor. American Journal of Hematology, 1987, 24, 107-109.	2.0	33
112	Evaluation of stored platelets. Vox Sanguinis, 2004, 86, 203-223.	0.7	33
113	The influence of riboflavin photochemistry on plasma coagulation factors. Transfusion and Apheresis Science, 2009, 41, 199-204.	0.5	33
114	Incidence of increased plasminogen activator inhibitor in patients with deep venous thrombosis and/or pulmonary embolism. Thrombosis Research, 1989, 56, 565-570.	0.8	32
115	Migraine and prothrombotic genetic risk factors. Cephalalgia, 1998, 18, 257-260.	1.8	32
116	Plasminogen activator inhibitor-1 levels in severe and morbid obesity. Effect of weight loss and influence of 4G/5G polymorphism. Thrombosis Research, 2008, 122, 320-327.	0.8	32
117	Management of antithrombin deficiency: an update for clinicians. Expert Review of Hematology, 2019, 12, 397-405.	1.0	32
118	Comparación de las ecuaciones de filtrado glomerular estimado para determinar la posología de los nuevos anticoagulantes orales para pacientes con fibrilación auricular. Revista Espanola De Cardiologia, 2015, 68, 497-504.	0.6	31
119	Does von Willebrand factor improve the predictive ability of current risk stratification scores in patients with atrial fibrillation?. Scientific Reports, 2017, 7, 41565.	1.6	31
120	Protein C levels in late pregnancy, postpartum and in women on oral contraceptives. Thrombosis Research, 1985, 39, 637-640.	0.8	30
121	Prothrombotic Genetic Risk Factors in Patients With Coexisting Migraine and Ischemic Cerebrovascular Disease. Headache, 1999, 39, 486-489.	1.8	30
122	The TFPI 536C →T Mutation Is not Associated with Increased Risk for Venous or Arterial Thrombosis. Thrombosis and Haemostasis, 2000, 83, 787-788.	1.8	30
123	Novel loci involved in platelet function and platelet count identified by a genome-wide study performed in children. Haematologica, 2011, 96, 1335-1343.	1.7	30
124	Association of the Thrombomodulin Gene c.1418C→T Polymorphism With Thrombomodulin Levels and With Venous Thrombosis Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1435-1440.	1.1	30
125	Thrombosis as a conformational disease. Haematologica, 2005, 90, 238-46.	1.7	30
126	ABO blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms. Haematologica, 2008, 93, 729-734.	1.7	29

#	ARTICLE	IF	CITATIONS
127	Functional and molecular characterization of inherited platelet disorders in the Iberian Peninsula: results from a collaborative study. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 213.	1.2	29
128	Significant Hypo-Responsiveness to GPVI and CLEC-2 Agonists in Pre-Term and Full-Term Neonatal Platelets and following Immune Thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1009-1020.	1.8	29
129	Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 627-644.	2.1	29
130	Potential Role of miRNAs in Developmental Haemostasis. <i>PLoS ONE</i> , 2011, 6, e17648.	1.1	29
131	Risk of thrombosis during pregnancy and post-partum in hereditary thrombophilia. <i>American Journal of Hematology</i> , 1994, 46, 151-152.	2.0	28
132	Quality assessment of platelet concentrates supplemented with second-messenger effectors. <i>Transfusion</i> , 1999, 39, 135-143.	0.8	28
133	Clinical and analytical relevance of the combination of prothrombin 20210A/A and factor V Leiden: results from a large family. <i>British Journal of Haematology</i> , 1999, 105, 560-563.	1.2	28
134	Effect of quercetin on platelet spreading on collagen and fibrinogen and on multiple platelet kinases. <i>FÅ-toterapÅ-Åç</i> , 2010, 81, 75-80.	1.1	28
135	En el camino de un mejor uso de los anticoagulantes en la fibrilaci3n auricular no valvular. Propuesta de modificaci3n del posicionamiento terap3utico UT/V4/23122013. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 551-553.	0.6	28
136	A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the "Real-World" vs Clinical Trials. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1065-1073.	1.4	28
137	Prognostic value of thrombin generation parameters in hospitalized COVID-19 patients. <i>Scientific Reports</i> , 2021, 11, 7792.	1.6	28
138	Synergistic association between hypercholesterolemia and the C46T factor XII polymorphism for developing premature myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2005, 94, 1294-1299.	1.8	27
139	A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2005, 45, 25-29.	1.2	27
140	Antithrombin Dublin (p.Val30Glu): a relatively common variant with moderate thrombosis risk of causing transient antithrombin deficiency. <i>Thrombosis and Haemostasis</i> , 2016, 116, 146-154.	1.8	27
141	Regulatory regions of SERPINC1 gene: Identification of the first mutation associated with antithrombin deficiency. <i>Thrombosis and Haemostasis</i> , 2012, 107, 430-437.	1.8	26
142	Delayed Recovery and Increased Severity of Paclitaxel-Induced Peripheral Neuropathy in Patients With Diabetes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 417-423.	2.3	26
143	Identification of two novel mutations in <i>RASGRP2</i> affecting platelet CalDAG-GEFI expression and function in patients with bleeding diathesis. <i>Platelets</i> , 2018, 29, 192-195.	1.1	26
144	Quantitative defect of glycoprotein Ib in severe cirrhotic patients. <i>American Journal of Hematology</i> , 1994, 45, 10-15.	2.0	25

#	ARTICLE	IF	CITATIONS
145	Role of factor XIII Val34Leu polymorphism in patients <45 years of age with acute myocardial infarction. American Journal of Cardiology, 2003, 91, 1242-1245.	0.7	25
146	Application of a new enzyme-linked immunosorbent assay for detection of total hepatitis C virus core antigen in blood donors. Transfusion Medicine, 2003, 13, 259-266.	0.5	25
147	Biological dosimetry and Bayesian analysis of chromosomal damage in thyroid cancer patients. Radiation Protection Dosimetry, 2007, 129, 372-380.	0.4	25
148	Cryopreservation Modifies Flow-Cytometric Analysis of Hemopoietic Cells. Vox Sanguinis, 1995, 68, 210-214.	0.7	24
149	Genetic Polymorphisms of Platelet Adhesive Molecules: Association with Breast Cancer Risk and Clinical Presentation. Breast Cancer Research and Treatment, 2003, 80, 145-154.	1.1	24
150	Platelet GP IIIa Polymorphism HPA-1 (PIA) Protects Against Subarachnoid Hemorrhage. Stroke, 2004, 35, 2282-2286.	1.0	24
151	Increased levels of citrullinated antithrombin in plasma of patients with rheumatoid arthritis and colorectal adenocarcinoma determined by a newly developed ELISA using a specific monoclonal antibody. Thrombosis and Haemostasis, 2010, 104, 1143-1149.	1.8	24
152	Evaluation of pooled platelet concentrates using prestorage versus poststorage WBC reduction: impact of filtration timing. Transfusion, 2000, 40, 781-788.	0.8	23
153	Chediak-Higashi syndrome: description of two novel homozygous missense mutations causing divergent clinical phenotype. European Journal of Haematology, 2014, 92, 49-58.	1.1	23
154	Real-life management of primary immune thrombocytopenia (ITP) in adult patients and adherence to practice guidelines. Annals of Hematology, 2016, 95, 1089-1098.	0.8	23
155	microRNAs in the haemostatic system: More than witnesses of thromboembolic diseases?. Thrombosis Research, 2018, 166, 1-9.	0.8	23
156	New alleles of the platelet glycoprotein I β gene. British Journal of Haematology, 1998, 103, 997-1003.	1.2	22
157	Polymorphisms of Platelet Adhesive Receptors: Do They Play a Role in Primary Intracerebral Hemorrhage?. Cerebrovascular Diseases, 2003, 15, 51-55.	0.8	22
158	Deep venous thrombosis or pulmonary embolism and factor V Leiden: enigma or paradox. Haematologica, 2010, 95, 863-866.	1.7	22
159	High incidence of FXI deficiency in a Spanish town caused by 11 different mutations and the first duplication of F11: Results from the Yecla study. Haemophilia, 2017, 23, e488-e496.	1.0	22
160	Enhancing the "real world" prediction of cardiovascular events and major bleeding with the CHA ₂ DS ₂ -VASc and HAS-BLED scores using multiple biomarkers. Annals of Medicine, 2018, 50, 26-34.	1.5	22
161	Detection of conformational transformation of antithrombin in blood with crossed immunoelectrophoresis: new application for a classical method. Translational Research, 2003, 142, 298-305.	2.4	21
162	Poly(ADP-ribose) polymerase-1 inhibition increases expression of heat shock proteins and attenuates heat stroke-induced liver injury. Critical Care Medicine, 2008, 36, 526-534.	0.4	21

#	ARTICLE	IF	CITATIONS
163	Dexamethasone induces a heat-stress response that ameliorates the conformational consequences on antithrombin of l-asparaginase treatment. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1128-1133.	1.9	21
164	Ankle brachial index as an independent predictor of mortality in anticoagulated atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2012, 42, 1302-1308.	1.7	21
165	Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol. <i>Clinical Therapeutics</i> , 2018, 40, 114-122.	1.1	21
166	Incidence and features of thrombosis in children with inherited antithrombin deficiency. <i>Haematologica</i> , 2019, 104, 2512-2518.	1.7	21
167	Relation between human LPIN1, hypoxia and endoplasmic reticulum stress genes in subcutaneous and visceral adipose tissue. <i>International Journal of Obesity</i> , 2010, 34, 679-686.	1.6	20
168	Lipodystrophy and Insulin Resistance in Combination Antiretroviral Treated HIV-1â€“Infected Patients: Implication of Resistin. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 57, 16-23.	0.9	20
169	Type II antithrombin deficiency caused by a large in-frame insertion: structural, functional and pathological relevance. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1859-1866.	1.9	20
170	The prognostic role of the adiponectin levels in atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2013, 43, 168-173.	1.7	20
171	Negative-Pressure Therapy in the Postoperative Treatment of Incisional Hernioplasty Wounds. <i>Advances in Skin and Wound Care</i> , 2014, 27, 77-80.	0.5	20
172	Puzzling questions on antithrombin: Diagnostic limitations and real incidence in venous and arterial thrombosis. <i>Thrombosis Research</i> , 2015, 135, 1047-1048.	0.8	20
173	Regulation of TFPÎ± expression by miR-27a/b-3p in human endothelial cells under normal conditions and in response to androgens. <i>Scientific Reports</i> , 2017, 7, 43500.	1.6	20
174	High levels of latent antithrombin in plasma from patients with antithrombin deficiency. <i>Thrombosis and Haemostasis</i> , 2017, 117, 880-888.	1.8	20
175	An early increase of CD56^{bright} natural killer subset as dominant effect and predictor of response to extracorporeal photopheresis for graftâ€“versusâ€“host disease. <i>Transfusion</i> , 2018, 58, 2924-2932.	0.8	20
176	Influence of somatostatin in the evolution of acute pancreatitis. <i>International Journal of Gastrointestinal Cancer</i> , 1994, 15, 139-44.	0.4	19
177	Impact of whole-body 18F-FDG PET on diagnostic and therapeutic management of Medical Oncology patients. <i>European Journal of Cancer</i> , 2008, 44, 1678-1683.	1.3	19
178	Rare homozygous status of P43 Î²1-tubulin polymorphism causes alterations in platelet ultrastructure. <i>Thrombosis and Haemostasis</i> , 2011, 105, 855-863.	1.8	19
179	High on-treatment platelet reactivity in patients with ischemic cerebrovascular disease. <i>Blood Coagulation and Fibrinolysis</i> , 2014, 25, 604-611.	0.5	19
180	sST2 levels are associated with allâ€“cause mortality in anticoagulated patients with atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2015, 45, 899-905.	1.7	19

#	ARTICLE	IF	CITATIONS
181	Effects of conventional neoadjuvant chemotherapy for breast cancer on tumor angiogenesis. Breast Cancer Research and Treatment, 2015, 151, 577-587.	1.1	19
182	MiRNA-Based Regulation of Hemostatic Factors through Hepatic Nuclear Factor-4 Alpha. PLoS ONE, 2016, 11, e0154751.	1.1	19
183	Impaired leucocyte activation is underlining the lower thrombotic risk of essential thrombocythaemia patients with <i>CALR</i> mutations as compared with those with the <i>JAK2</i> mutation. British Journal of Haematology, 2016, 172, 813-815.	1.2	19
184	Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation. American Journal of Cardiology, 2017, 120, 2176-2181.	0.7	19
185	Wiskottâ€Aldrich syndrome in a child presenting with macrothrombocytopenia. Platelets, 2017, 28, 417-420.	1.1	19
186	Down Regulation of the Munc18b-syntaxin-11 Complex and Î²1-tubulin Impairs Secretion and Spreading in Neonatal Platelets. Thrombosis and Haemostasis, 2017, 117, 2079-2091.	1.8	19
187	Qualitative and Quantitative Comparison of Plasma Exosomes from Neonates and Adults. International Journal of Molecular Sciences, 2021, 22, 1926.	1.8	19
188	CEREBROSPINAL FLUID LEVELS BETA2MICROGLOBULIN AND FERRITIN IN LYMPHOPROLIVERATIVE DISORDERS. Acta Paediatrica, International Journal of Paediatrics, 1982, 71, 325-326.	0.7	18
189	Short alleles of P-selectin glycoprotein ligand-1 protect against premature myocardial infarction. American Heart Journal, 2004, 148, 602-605.	1.2	18
190	Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in â€real-worldâ€™ atrial fibrillation patients: A comparison with optimally acenocoumarol anticoagulated patients. International Journal of Cardiology, 2018, 254, 125-131.	0.8	18
191	Elevated thrombin generation in patients with congenital disorder of glycosylation and combined coagulation factor deficiencies. Journal of Thrombosis and Haemostasis, 2019, 17, 1798-1807.	1.9	18
192	Platelet Cryopreservation Using a Reduced Dimethyl Sulfoxide Concentration and Second-Messenger Effectors as Cryopreserving Solution. Cryobiology, 1999, 39, 1-12.	0.3	17
193	Safety evaluation and nutritional composition of a Fraxinus excelsior seed extract, FraxiPureâ„¢. Food and Chemical Toxicology, 2013, 53, 10-17.	1.8	17
194	Comparison of Estimated Glomerular Filtration Rate Equations for Dosing New Oral Anticoagulants in Patients With Atrial Fibrillation. Revista Espanola De Cardiologia (English Ed), 2015, 68, 497-504.	0.4	17
195	On the necessity of new decision-making methods for cancer-associated, symptomatic, pulmonary embolism. Thrombosis Research, 2016, 143, 76-85.	0.8	17
196	Genetic predisposition to fetal alcohol syndrome: association with congenital disorders of N-glycosylation. Pediatric Research, 2018, 83, 119-127.	1.1	17
197	MicroRNAs as New Regulators of Neutrophil Extracellular Trap Formation. International Journal of Molecular Sciences, 2021, 22, 2116.	1.8	17
198	Five prothrombotic polymorphisms and the prevalence of premature myocardial infarction. Haematologica, 2005, 90, 421-3.	1.7	17

#	ARTICLE	IF	CITATIONS
199	Repeated infusions of DDAVP induce low response of FVIII and vWF but not of plasminogen activators. <i>Thrombosis Research</i> , 1993, 70, 117-122.	0.8	16
200	Association of autoantibodies against platelet glycoproteins Ib/IX and IIb/IIIa, and platelet-reactive anti-HIV antibodies in thrombocytopenic narcotic addicts. <i>British Journal of Haematology</i> , 1996, 93, 464-471.	1.2	16
201	Genotype-phenotype relationship for six common polymorphisms in genes affecting platelet function from 286 healthy subjects and 160 patients with mucocutaneous bleeding of unknown cause. <i>British Journal of Haematology</i> , 2009, 146, 95-103.	1.2	16
202	Influencia de los polimorfismos de CYP2C19 en la reactividad plaquetaria y el pronóstico en una población no seleccionada de pacientes con síndrome coronario agudo sin elevación del ST. <i>Revista Española De Cardiología</i> , 2012, 65, 219-226.	0.6	16
203	Persistent cytotoxic T lymphocyte expansions after allogeneic haematopoietic stem cell transplantation: kinetics, clinical impact and absence of <i>STAT3</i> mutations. <i>British Journal of Haematology</i> , 2016, 172, 937-946.	1.2	16
204	Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation. <i>Scientific Reports</i> , 2017, 7, 12066.	1.6	16
205	miR-146a deficiency in hematopoietic cells is not involved in the development of atherosclerosis. <i>PLoS ONE</i> , 2018, 13, e0198932.	1.1	16
206	Underlying disorders of disseminated intravascular coagulation: Communication from the ISTH SSC Subcommittees on Disseminated Intravascular Coagulation and Perioperative and Critical Care Thrombosis and Hemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2400-2407.	1.9	16
207	A pilot study on the impact of congenital thrombophilia in COVID-19. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13546.	1.7	16
208	Factors with conformational effects on haemostatic serpins: Implications in thrombosis. <i>Thrombosis and Haemostasis</i> , 2007, 98, 557-563.	1.8	16
209	Novel Associations of VKORC1 Variants with Higher Acenocoumarol Requirements. <i>PLoS ONE</i> , 2013, 8, e64469.	1.1	16
210	Activated protein C:1-antitrypsin (APC:1AT) complex as a marker for diagnosis of prethrombotic states. <i>Thrombosis Research</i> , 1992, 66, 499-508.	0.8	15
211	Role of Genetic Polymorphisms in NFKB-Mediated Inflammatory Pathways in Response to Primary Chemoradiation Therapy for Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 595-602.	0.4	15
212	Proteomic analysis of platelet N-glycoproteins in PMM2-CDG patients. <i>Thrombosis Research</i> , 2014, 133, 412-417.	0.8	15
213	Comparative study of open abdomen treatment: ABThera vs. abdominal dressing. <i>Hernia: the Journal of Hernias and Abdominal Wall Surgery</i> , 2015, 19, 323-328.	0.9	15
214	Disease-causing mutations in the serpin antithrombin reveal a key domain critical for inhibiting protease activities. <i>Journal of Biological Chemistry</i> , 2017, 292, 16513-16520.	1.6	15
215	Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia. <i>Scientific Reports</i> , 2019, 9, 16680.	1.6	15
216	Neutrophil extracellular traps and von Willebrand factor are allies that negatively influence COVID-19 outcomes. <i>Clinical and Translational Medicine</i> , 2021, 11, e268.	1.7	15

#	ARTICLE	IF	CITATIONS
217	Implications of Pharmacogenetics for Oral Anticoagulants Metabolism. <i>Current Drug Metabolism</i> , 2009, 10, 632-642.	0.7	15
218	Evaluation of platelet function during extended storage in additive solution, prepared in a new container that allows manual buffy-coat platelet pooling and leucoreduction in the same system. <i>Blood Transfusion</i> , 2012, 10, 480-9.	0.3	15
219	Factor VII ϵ 323 decanucleotide D/I polymorphism in atrial fibrillation: Implications for the prothrombotic state and stroke risk. <i>Annals of Medicine</i> , 2008, 40, 553-559.	1.5	14
220	Predictive Value of the CHA2DS2-VASc Score in Atrial Fibrillation Patients at High Risk for Stroke Despite Oral Anticoagulation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012, 65, 627-633.	0.4	14
221	Protective role of antithrombin in mouse models of liver injury. <i>Journal of Hepatology</i> , 2012, 57, 980-986.	1.8	14
222	The Infective Polymerization of Conformationally Unstable Antithrombin Mutants May Play a Role in the Clinical Severity of Antithrombin Deficiency. <i>Molecular Medicine</i> , 2012, 18, 762-770.	1.9	14
223	Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: clonal evolution and hierarchy revealed by next-generation sequencing. <i>Journal of Hematology and Oncology</i> , 2013, 6, 68.	6.9	14
224	Soluble Fibrin Monomer Complex and Prediction of Cardiovascular Events in Atrial Fibrillation: The Observational Murcia Atrial Fibrillation Project. <i>Journal of General Internal Medicine</i> , 2018, 33, 847-854.	1.3	14
225	MicroRNAs as potential regulators of platelet function and bleeding diatheses. <i>Platelets</i> , 2019, 30, 803-808.	1.1	14
226	Autoaggression syndrome resembling acute graft-versus-host disease grade IV after autologous peripheral blood stem cell transplantation for breast cancer. <i>Bone Marrow Transplantation</i> , 1999, 23, 621-624.	1.3	13
227	Effect of Factor XIII VAL34LEU Polymorphism on Thrombolytic Therapy in Premature Myocardial Infarction. <i>Thrombosis and Haemostasis</i> , 2002, 88, 354-355.	1.8	13
228	Synergistic Effect of Diosmin and Interferon- β on Metastatic Pulmonary Melanoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 347-352.	0.7	13
229	Congenital disorder of glycosylation (PMM2-CDG) in a patient with antithrombin deficiency and severe thrombophilia. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2625-2627.	1.9	13
230	Influence of oral health on mucositis in patients undergoing hematopoietic progenitor cell transplantation (HPCT). <i>Medicina Oral, Patologia Oral Y Cirugia Bucal</i> , 2012, 17, e94-e101.	0.7	13
231	Polymorphisms in xenobiotic metabolizing genes (EPHX1, NQO1 and PON1) in lymphoma susceptibility: a case control study. <i>BMC Cancer</i> , 2013, 13, 228.	1.1	13
232	GPI-anchor and GPI-anchored protein expression in PMM2-CDG patients. <i>Orphanet Journal of Rare Diseases</i> , 2013, 8, 170.	1.2	13
233	Association of polymorphisms in TRAIL1 and TRAILR1 genes with susceptibility to lymphomas. <i>Annals of Hematology</i> , 2014, 93, 243-247.	0.8	13
234	Differential miRNA expression profile and proteome in plasma exosomes from patients with paroxysmal nocturnal hemoglobinuria. <i>Scientific Reports</i> , 2019, 9, 3611.	1.6	13

#	ARTICLE	IF	CITATIONS
235	Neutrophil extracellular trap components increase the expression of coagulation factors. <i>Biomedical Reports</i> , 2019, 10, 195-201.	0.9	13
236	Role of Factor XIII Val 34 Leu Polymorphism in Patients with Migraine. <i>Cephalalgia</i> , 2001, 21, 837-841.	1.8	12
237	Nonsense Mutation in Exon-19 of GPIIb Associated with Thrombasthenic Phenotype. Failure of GPIIb(Î ⁿ 597-1008) to Form Stable Complexes with GPIIIa. <i>Thrombosis and Haemostasis</i> , 2002, 87, 684-691.	1.8	12
238	The A>T mutation in the annexin A5 gene does not affect plasma levels of annexin A5. <i>Blood</i> , 2003, 101, 4223-4224.	0.6	12
239	Experimental model of pulmonary metastasis treatment with IFNÎ±. <i>Cancer Letters</i> , 2005, 225, 75-83.	3.2	12
240	In vivo effects of hyperthermia on the functional and conformational characteristics of antithrombin. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 963-970.	1.9	12
241	CALU A29809G polymorphism in coronary atherothrombosis: Implications for coronary calcification and prognosis. <i>Annals of Medicine</i> , 2010, 42, 439-446.	1.5	12
242	Home Treatment of Uncomplicated Acute Diverticulitis. <i>International Surgery</i> , 2012, 97, 203-209.	0.0	12
243	Î ² -Trace Protein and Prognosis in Patients With Atrial Fibrillation Receiving Anticoagulation Treatment. <i>Chest</i> , 2013, 144, 1564-1570.	0.4	12
244	Identification of Regulatory Mutations in SERPINC1 Affecting Vitamin D Response Elements Associated with Antithrombin Deficiency. <i>PLoS ONE</i> , 2016, 11, e0152159.	1.1	12
245	Assessment of two contact activation reagents for the diagnosis of congenital factor XI deficiency. <i>Thrombosis Research</i> , 2018, 163, 64-70.	0.8	12
246	Increasing therapy-related myeloid neoplasms in multiple myeloma. <i>European Journal of Clinical Investigation</i> , 2018, 49, e13050.	1.7	12
247	First exploratory study on the metabolome from plasma exosomes in patients with paroxysmal nocturnal hemoglobinuria. <i>Thrombosis Research</i> , 2019, 183, 80-85.	0.8	12
248	RASGRP2 gene variations associated with platelet dysfunction and bleeding. <i>Platelets</i> , 2019, 30, 535-539.	1.1	12
249	MPI-CDG with transient hypoglycosylation and antithrombin deficiency. <i>Haematologica</i> , 2019, 104, e79-e82.	1.7	12
250	Developmental Differences in Platelet Inhibition Response to Prostaglandin E1. <i>Neonatology</i> , 2020, 117, 15-23.	0.9	12
251	ALG12-CDG: An unusual patient without intellectual disability and facial dysmorphism, and with a novel variant. <i>Molecular Genetics & Genomic Medicine</i> , 2020, 8, e1304.	0.6	12
252	Frozen and cold-stored platelets: reconsidered platelet products. <i>Platelets</i> , 2022, 33, 27-34.	1.1	12

#	ARTICLE	IF	CITATIONS
253	Expanding the genetic spectrum of <i>TUBB1</i> -related thrombocytopenia. <i>Blood Advances</i> , 2021, 5, 5453-5467.	2.5	12
254	Administration of post-autologous PBSCT rhG-CSF is associated with long-term low concentrations of bone marrow hematopoietic progenitor cells. <i>Bone Marrow Transplantation</i> , 2001, 27, 1287-1292.	1.3	11
255	Evaluation of a new whole-blood filter that allows preparation of platelet concentrates by platelet-rich plasma methods. <i>Transfusion</i> , 2003, 43, 1723-1728.	0.8	11
256	JAK2 V617F, hemostatic polymorphisms, and clinical features as risk factors for arterial thrombotic events in essential thrombocythemia. <i>Annals of Hematology</i> , 2008, 87, 763-765.	0.8	11
257	Inhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin. <i>Laboratory Investigation</i> , 2008, 88, 306-317.	1.7	11
258	Influence of the F12-4 C>T polymorphism on hemostatic tests. <i>Blood Coagulation and Fibrinolysis</i> , 2010, 21, 632-639.	0.5	11
259	Heparin affinity of factor VIIa: Implications on the physiological inhibition by antithrombin and clearance of recombinant factor VIIa. <i>Thrombosis Research</i> , 2011, 127, 154-160.	0.8	11
260	Identification of novel variants in ten patients with Hermansky-Pudlak syndrome by high-throughput sequencing. <i>Annals of Medicine</i> , 2019, 51, 141-148.	1.5	11
261	Pilot Study on the Role of Circulating miRNAs for the Improvement of the Predictive Ability of the 2MACE Score in Patients with Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2020, 9, 3645.	1.0	11
262	Increased N-Glycosylation Efficiency by Generation of an Aromatic Sequon on N135 of Antithrombin. <i>PLoS ONE</i> , 2014, 9, e114454.	1.1	11
263	miR-146a in Cardiovascular Diseases and Sepsis: An Additional Burden in the Inflammatory Balance?. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1138-1150.	1.8	11
264	Latent and polymeric antithrombin: clearance and potential thrombotic risk. <i>Experimental Biology and Medicine</i> , 2007, 232, 219-26.	1.1	11
265	Two <i>SERPINC1</i> variants affecting N-glycosylation of Asn224 cause severe thrombophilia not detected by functional assays. <i>Blood</i> , 2022, 140, 140-151.	0.6	11
266	Molecular, ultrastructural and functional characterization of a Spanish family with Hermansky-Pudlak syndrome: role of insC974 in platelet function and clinical relevance. <i>British Journal of Haematology</i> , 2003, 123, 132-138.	1.2	10
267	Intracellular retention of hepatic serpins caused by severe hyperlipidemia. <i>Liver International</i> , 2006, 26, 708-715.	1.9	10
268	IgM monoclonal component associated with type I Gaucher disease resolved after enzyme replacement therapy: A case report. <i>Journal of Inherited Metabolic Disease</i> , 2009, 32, 265-267.	1.7	10
269	Control of post-translational modifications in antithrombin during murine post-natal development by miR-200a. <i>Journal of Biomedical Science</i> , 2013, 20, 29.	2.6	10
270	Prognostic signature and clonality pattern of recurrently mutated genes in inactive chronic lymphocytic leukemia. <i>Blood Cancer Journal</i> , 2015, 5, e342-e342.	2.8	10

#	ARTICLE	IF	CITATIONS
271	Genotype-guided therapy improves initial acenocoumarol dosing. <i>Thrombosis and Haemostasis</i> , 2016, 115, 117-125.	1.8	10
272	On the Way to a Better Use of Anticoagulants in Nonvalvular Atrial Fibrillation. Proposed Amendment to the Therapeutic Positioning Report ÚT/V4/23122013. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 551-553.	0.4	10
273	Defects of splicing in antithrombin deficiency. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017, 1, 216-222.	1.0	10
274	Congenital antithrombin deficiency in patients with splanchnic vein thrombosis. <i>Liver International</i> , 2020, 40, 1168-1177.	1.9	10
275	N-Glycosylation as a Tool to Study Antithrombin Secretion, Conformation, and Function. <i>International Journal of Molecular Sciences</i> , 2021, 22, 516.	1.8	10
276	Recomendaciones del Grupo Espa±ol de PTI para el diagn³stico, tratamiento y seguimiento de pacientes con trombocitopenia inmune. <i>Medicina ClÁnica</i> , 2021, 157, 191-198.	0.3	10
277	Factor XIII Val34Leu polymorphism in primary intracerebral haemorrhage. <i>The Hematology Journal</i> , 2000, 1, 269-273.	2.0	10
278	Molecular and clinical characterization of transient antithrombin deficiency: A new concept in congenital thrombophilia. <i>American Journal of Hematology</i> , 2022, 97, 216-225.	2.0	10
279	Protein c and antithrombin III in acute myocardial infarction. <i>Thrombosis Research</i> , 1986, 43, 681-685.	0.8	9
280	Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotherapeutic agent, associated with rhG-CSF. <i>Bone Marrow Transplantation</i> , 2000, 25, 231-235.	1.3	9
281	Effects of acrolein, a natural occurring aldehyde, on the anticoagulant serpin antithrombin. <i>FEBS Letters</i> , 2009, 583, 3165-3170.	1.3	9
282	Role of <i>CSTT1</i> and <i>M1</i> null genotypes as risk factors for Bâ€cell lymphoma: Influence of geographical factors and occupational exposure. <i>Molecular Carcinogenesis</i> , 2012, 51, 508-513.	1.3	9
283	Quality assessment of buffyâ€coatâ€derived leucodepleted platelet concentrates in <sc>PAS</sc>â€plasma, prepared by the <sc>O</sc>ri<sc>S</sc>ac or <sc>TACSI</sc> automated system. <i>Vox Sanguinis</i> , 2014, 106, 38-44.	0.7	9
284	The JAK2 46/1 haplotype does not predispose to CALR-mutated myeloproliferative neoplasms. <i>Annals of Hematology</i> , 2015, 94, 789-794.	0.8	9
285	Prognostic value of computed tomography pulmonary angiography indices in patients with cancer-related pulmonary embolism: Data from a multicenter cohort study. <i>European Journal of Radiology</i> , 2017, 87, 66-75.	1.2	9
286	The FXII c.-4T>C Polymorphism as a Disease Modifier in Patients With Hereditary Angioedema Due to the FXII p.Thr328Lys Variant. <i>Frontiers in Genetics</i> , 2020, 11, 1033.	1.1	9
287	Factor XII in PMM2-CDC patients: role of N-glycosylation in the secretion and function of the first element of the contact pathway. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 280.	1.2	9
288	Identification of Antithrombin-Modulating Genes. Role of LARGE, a Gene Encoding a Bifunctional Glycosyltransferase, in the Secretion of Proteins?. <i>PLoS ONE</i> , 2013, 8, e64998.	1.1	9

#	ARTICLE	IF	CITATIONS
289	Long-Read Sequencing Identifies the First Retrotransposon Insertion and Resolves Structural Variants Causing Antithrombin Deficiency. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1369-1378.	1.8	9
290	Effect of rhG-CSF on the mobilization of CD38 and HLA-DR subfractions of CD34+ peripheral blood progenitor cells. <i>Annals of Hematology</i> , 1995, 71, 105-110.	0.8	8
291	In Vitro Changes of Platelet Parameters: Lessons From Blood Banking. , 2004, 273, 057-072.		8
292	Protein Z-dependent protease inhibitor W303X mutation in venous thrombosis. <i>British Journal of Haematology</i> , 2005, 129, 561-562.	1.2	8
293	Hyperglycaemia impairs antithrombin secretion: Possible contribution to the thrombotic risk of diabetes. <i>Thrombosis Research</i> , 2009, 124, 483-489.	0.8	8
294	Role of the C—sheet in the maturation of N—glycans on antithrombin: functional relevance of pleiotropic mutations. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1131-1140.	1.9	8
295	Effect ofVKORC1, CYP2C9andCYP4F2genetic variants in early outcomes during acenocoumarol treatment. <i>Pharmacogenomics</i> , 2014, 15, 987-996.	0.6	8
296	Identification of a new potential mechanism responsible for severe bleeding in myeloma: immunoglobulins bind the heparin binding domain of antithrombin activating this endogenous anticoagulant. <i>Haematologica</i> , 2016, 101, e423-e426.	1.7	8
297	Generation of induced pluripotent stem cells (iPSCs) from a Bernard—Soulier syndrome patient carrying a W71R mutation in the GPIX gene. <i>Stem Cell Research</i> , 2016, 16, 692-695.	0.3	8
298	Prediction of long-term net clinical outcomes using the TIMI-AF score: Comparison with CHA 2 DS 2 -VAsc and HAS-BLED. <i>American Heart Journal</i> , 2018, 197, 27-34.	1.2	8
299	Platelet activation and neutrophil extracellular trap (NET) formation in immune thrombocytopenia: is there an association?. <i>Platelets</i> , 2020, 31, 906-912.	1.1	8
300	Particulate Matter and Temperature: Increased Risk of Adverse Clinical Outcomes in Patients With Atrial Fibrillation. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2360-2369.	1.4	8
301	T cells subpopulations in untreated and treated patients with haemophilia A and B. <i>Blut</i> , 1983, 47, 311-313.	1.2	7
302	Regulation of the cytosolic and melanosome-bound tyrosinase activities in harding-passey mouse melanoma. <i>International Journal of Biochemistry & Cell Biology</i> , 1985, 17, 995-1002.	0.8	7
303	Oral Contraceptives Highlight the Genotype-Specific Association Between Serum Phospholipids and Activated Factor VII. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 2024-2028.	1.1	7
304	Evaluation of refrigerated platelet concentrates supplemented with low doses of second messenger effectors. <i>International Journal of Laboratory Hematology</i> , 2004, 26, 275-286.	0.2	7
305	A new method to quantify I ² -antithrombin glycoform in plasma reveals increased levels during the acute stroke event. <i>Thrombosis Research</i> , 2015, 136, 634-641.	0.8	7
306	Spanish consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria. <i>Medicina Cl&#x00c3;nica (English Edition)</i> , 2016, 146, 278.e1-278.e7.	0.1	7

#	ARTICLE	IF	CITATIONS
307	High penetrance of inferior vena cava system atresia in severe thrombophilia caused by homozygous antithrombin Budapest 3 variant: Description of a new syndrome. <i>American Journal of Hematology</i> , 2021, 96, 1363-1373.	2.0	7
308	Molecular Dissection of Structural Variations Involved in Antithrombin Deficiency. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 462-475.	1.2	7
309	Studies on platelet surface carbohydrates in normal and uraemic platelets using 125I-labelled lectins. <i>Blut</i> , 1985, 50, 287-292.	1.2	6
310	Kinin-Prekallikrein System in Mediterranean Spotted Fever. <i>Journal of Infectious Diseases</i> , 1986, 154, 541-541.	1.9	6
311	Thermochemotherapy for B16 Melanoma: Combination Therapy of Hyperthermia, Melphalan, and CCNU in Mice. <i>Pigment Cell & Melanoma Research</i> , 1990, 3, 1-7.	4.0	6
312	Complex formation between protein c inhibitor and tissue plasminogen activator during thrombolytic therapy. <i>Fibrinolysis</i> , 1993, 7, 308-315.	0.5	6
313	Fibrinolytic changes during acute vascular damage induced by Mediterranean spotted fever. <i>Fibrinolysis</i> , 1993, 7, 324-329.	0.5	6
314	Human platelet antigen systems in allogeneic peripheral blood progenitor cell transplantation: effect of human platelet antigen mismatch on platelet engraftment and graft-versus-host disease. <i>Transfusion</i> , 2004, 44, 771-776.	0.8	6
315	Prognostic value of annexin A5 ?1 C/T polymorphism in a long term follow-up after premature myocardial infarction. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 862-863.	1.9	6
316	TUBB1 Q43P polymorphism does not protect against acute coronary syndrome and premature myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2008, 100, 1211-1213.	1.8	6
317	Influence of CYP2C19 Polymorphisms in Platelet Reactivity and Prognosis in an Unselected Population of Non ST Elevation Acute Coronary Syndrome. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012, 65, 219-226.	0.4	6
318	Heparanase Activates Antithrombin through the Binding to Its Heparin Binding Site. <i>PLoS ONE</i> , 2016, 11, e0157834.	1.1	6
319	Allogeneic hematopoietic cell transplantation in an adult patient with Glanzmann thrombasthenia. <i>Clinical Case Reports (discontinued)</i> , 2017, 5, 1887-1890.	0.2	6
320	Identification of the first large intronic deletion responsible of type I antithrombin deficiency not detected by routine molecular diagnostic methods. <i>British Journal of Haematology</i> , 2019, 186, e82-e86.	1.2	6
321	Archeogenetics of F11 p.Cys38Arg: a 5400-year-old mutation identified in different southwestern European countries. <i>Blood</i> , 2019, 133, 2618-2622.	0.6	6
322	Cancer testis antigens in myelodysplastic syndromes revisited: a targeted RNA-seq approach. <i>Oncolmmunology</i> , 2020, 9, 1824642.	2.1	6
323	<i>PTGS1</i> gene variations associated with bleeding and platelet dysfunction. <i>Platelets</i> , 2021, 32, 710-716.	1.1	6
324	Antithrombin p.Thr147Ala: The First Founder Mutation in People of African Origin Responsible for Inherited Antithrombin Deficiency. <i>Thrombosis and Haemostasis</i> , 2021, 121, 182-191.	1.8	6

#	ARTICLE	IF	CITATIONS
325	Anti-Tumor Functions of Prelatent Antithrombin on Glioblastoma Multiforme Cells. <i>Biomedicines</i> , 2021, 9, 523.	1.4	6
326	Minimal Residual Disease in Multiple Myeloma: Something Old, Something New. <i>Cancers</i> , 2021, 13, 4332.	1.7	6
327	Fatal upper and lower gastrointestinal cytomegalovirus disease following autologous peripheral blood stem cell transplantation. <i>European Journal of Haematology</i> , 2001, 66, 130-132.	1.1	6
328	Gynaecological and obstetrical bleeding in Caucasian women with congenital factor XI deficiency: Results from a twenty-year, retrospective, observational study. <i>Medicina Clínica</i> , 2019, 153, 373-379.	0.3	6
329	Implication of Hepsin from Primary Tumor in the Prognosis of Colorectal Cancer Patients. <i>Cancers</i> , 2022, 14, 3106.	1.7	6
330	Ulcer necrotic legs as first manifestation of protein S deficiency. <i>Blut</i> , 1987, 54, 253-254.	1.2	5
331	Ultrastructural Study of Melanocytic Lesions in Albino Guinea Pigs Induced with 7,12-Dimethyl-Benzanthracene. <i>Ultrastructural Pathology</i> , 1989, 13, 43-53.	0.4	5
332	Comparative Study of Three Methods to Detect Free Plasma Antiplatelet Antibodies. <i>Acta Haematologica</i> , 1996, 96, 135-139.	0.7	5
333	Coexistence of three genetic risk factors in a Spanish thrombophilic family: Factor V Leiden, prothrombin 20210 and a new type I antithrombin deficiency. <i>Thrombosis and Haemostasis</i> , 2007, 97, 153-155.	1.8	5
334	Leukaemic Transformation in Patients with Haematological Disease Receiving Tumour Necrosis Factor Inhibitors. <i>Clinical Drug Investigation</i> , 2012, 32, 423-426.	1.1	5
335	Adult Intussusception of Appendicular Mucinous Cystoadenoma. <i>International Surgery</i> , 2013, 98, 392-398.	0.0	5
336	An atypical IgM class platelet cold agglutinin induces GPVI-dependent aggregation of human platelets. <i>Thrombosis and Haemostasis</i> , 2015, 114, 313-324.	1.8	5
337	Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method. <i>Annals of Hematology</i> , 2016, 95, 719-732.	0.8	5
338	Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12929.	1.7	5
339	Identification of a New Mechanism of Antithrombin Deficiency Hardly Detected by Current Methods: Duplication of SERPINC1 Exon 6. <i>Thrombosis and Haemostasis</i> , 2018, 118, 939-941.	1.8	5
340	Transcriptomic rationale for synthetic lethality targeting <i>ERCC1</i> and <i>CDKN1A</i> in chronic myelomonocytic leukaemia. <i>British Journal of Haematology</i> , 2018, 182, 373-383.	1.2	5
341	Identification of Circulating microRNA Signatures As Potential Noninvasive Biomarkers for Prediction to Response to Extracorporeal Photoapheresis in Patients with Graft Versus Host Disease. <i>Blood</i> , 2019, 134, 4466-4466.	0.6	5
342	Absence of Effect of DDAVP Infusion on Platelet Glycoprotein Ib/IX and IIb/IIIa Complexes, and their Interaction with Newly Released von Willebrand Factor. <i>Platelets</i> , 1993, 4, 219-224.	1.1	4

#	ARTICLE	IF	CITATIONS
343	Bone marrow steady-state CD34+/CD71 ^{hi} cell content is a predictive value of rG-CSF-mobilized CD34+ cells. <i>Bone Marrow Transplantation</i> , 1998, 21, 983-985.	1.3	4
344	Aplastic Anaemia Induced by Ticlopidine after Placement of Coronary Artery Stents. <i>Clinical Drug Investigation</i> , 1998, 15, 261-262.	1.1	4
345	In vitro analysis of platelet concentrates stored in the presence of modulators of 3 rd , 5 th adenosine monophosphate, and organic anions. <i>Transfusion Science</i> , 2000, 22, 3-11.	0.6	4
346	Genetic variants of the extra-large stimulatory Gs protein alpha-subunit and risk of thrombotic and haemorrhagic disorders. <i>British Journal of Haematology</i> , 2004, 125, 621-628.	1.2	4
347	Effect of factor VII -323 Del/Ins polymorphism on the daily variability of factor VIIc and INR in steady anticoagulated patients with acenocoumarol. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 2264-2265.	1.9	4
348	β-glutamyl carboxylase R325Q polymorphism on the response of acenocoumarol. <i>Thrombosis Research</i> , 2008, 122, 429-431.	0.8	4
349	Successful mobilization of hematopoietic peripheral blood progenitor cells with paclitaxel-based chemotherapy as initial or salvage regimen in patients with hematologic malignancies. <i>Haematologica</i> , 2008, 93, 1436-1438.	1.7	4
350	Bone-marrow immunophenotypic analysis allows the identification of high risk of progression and immune condition-related monoclonal gammopathy of undetermined significance. <i>Annals of Medicine</i> , 2009, 41, 547-558.	1.5	4
351	Quality of life in patients operated on for digestive neoplasia: a prospective study. <i>Colorectal Disease</i> , 2012, 14, e470-6.	0.7	4
352	Transient desialylation in combination with a novel antithrombin deficiency causing a severe and recurrent thrombosis despite anticoagulation therapy. <i>Scientific Reports</i> , 2017, 7, 44556.	1.6	4
353	Antiplatelet therapy combined with acenocoumarol in relation to major bleeding, ischaemic stroke and mortality. <i>International Journal of Clinical Practice</i> , 2018, 72, e13069.	0.8	4
354	The prognostic impact of additional intrathoracic findings in patients with cancer-related pulmonary embolism. <i>Clinical and Translational Oncology</i> , 2018, 20, 230-242.	1.2	4
355	An increased percentage of myeloid CD34+ bone marrow cells stratifies intermediate IPSS-R myelodysplastic syndrome patients into prognostically significant groups. <i>International Journal of Laboratory Hematology</i> , 2018, 40, 549-555.	0.7	4
356	A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 86, 102505.	0.6	4
357	Polymorphisms of Platelet Membrane Glycoprotein Ib Associated With Arterial Thrombotic Disease. <i>Blood</i> , 1998, 92, 2771-2776.	0.6	4
358	Bacteremia in adult cancer patients with apparently stable febrile neutropenia: data from a cohort of 692 consecutive episodes from a single institution. <i>Journal of Community and Supportive Oncology</i> , 2014, 12, 312-320.	0.1	4
359	Identification of Thrombosis-Related Genes in Patients with Advanced Gastric Cancer: Data from AGAMENON-SEOM Registry. <i>Biomedicines</i> , 2022, 10, 148.	1.4	4
360	Factors with conformational effects on haemostatic serpins: implications in thrombosis. <i>Thrombosis and Haemostasis</i> , 2007, 98, 557-63.	1.8	4

#	ARTICLE	IF	CITATIONS
361	Prognostic and Predictive Effects of Tumor and Plasma miR-200c-3p in Locally Advanced and Metastatic Breast Cancer. <i>Cancers</i> , 2022, 14, 2390.	1.7	4
362	High levels of circulating von willebrand factor inhibit the release of this protein but not of plasminogen activator after DDAVP. <i>Thrombosis Research</i> , 1985, 38, 101-105.	0.8	3
363	Melanocytic Carcinogenesis in Albino Guinea Pigs. <i>Pigment Cell & Melanoma Research</i> , 1988, 1, 390-396.	4.0	3
364	Factor-V (Arg ⁵⁰⁶ →Gln) Mutation in Ischemic Cerebrovascular Disease. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1997, 27, 105-111.	0.5	3
365	Platelet aggregation through prothrombinase activation induced by non-aggregant doses of platelet agonists. <i>Blood Coagulation and Fibrinolysis</i> , 2002, 13, 95-103.	0.5	3
366	Transient massive peripheral blood blastosis in patient with renal clear-cell carcinoma after treatment with high-dose recombinant interleukin-2. <i>Lancet Oncology</i> , The, 2007, 8, 275-276.	5.1	3
367	Study of 18 functional hemostatic polymorphisms in mucocutaneous bleeding disorders. <i>Annals of Hematology</i> , 2010, 89, 1147-1154.	0.8	3
368	High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation: a reply to a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2414-2415.	1.9	3
369	Effects of oral anticoagulant therapy and haplotype 1 of the endothelial protein C receptor gene on activated protein C levels. <i>Thrombosis and Haemostasis</i> , 2012, 107, 448-457.	1.8	3
370	Evaluation of two-step haemoglobin screening with HemoCue for blood donor qualification in mobile collection sites. <i>Vox Sanguinis</i> , 2014, 107, 343-350.	0.7	3
371	Cost-per-responder analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia in Spain. <i>Medicina Clínica (English Edition)</i> , 2015, 144, 389-396.	0.1	3
372	Antithrombin is incorporated into exosomes produced by antithrombin non-expressing cells. <i>Biochimie</i> , 2019, 165, 245-249.	1.3	3
373	Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation. <i>BMJ Open</i> , 2019, 9, e033712.	0.8	3
374	Antithrombin deficiency as a still underdiagnosed thrombophilia: a primer for internists. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 868-877.	0.3	3
375	Biochemical and cellular consequences of the antithrombin p.Met1? mutation identified in a severe thrombophilic family. <i>Oncotarget</i> , 2018, 9, 33202-33214.	0.8	3
376	Src-related thrombocytopenia: a fine line between a megakaryocyte dysfunction and an immune-mediated disease. <i>Blood Advances</i> , 2022, 6, 5244-5255.	2.5	3
377	EVIDENCE OF DEGRADATION OF FACTOR VIII-ANTIGEN IN ASCITIC FLUID. <i>British Journal of Haematology</i> , 1983, 55, 555-557.	1.2	2
378	INHIBITOR OF PROTEIN C AND COMBINED DEFICIENCY OF FACTORS V AND VIII. <i>British Journal of Haematology</i> , 1983, 53, 686-686.	1.2	2

#	ARTICLE	IF	CITATIONS
379	EFFECT OF DDAVP ON CONTACT PHASE OF BLOOD COAGULATION. British Journal of Haematology, 1984, 56, 679-680.	1.2	2
380	A Radioreceptor Assay for Mass Measurement of Inositol (1,4,5)-Trisphosphate Using Saponin-Permeabilized Outdated Human Platelets. Analytical Biochemistry, 1998, 256, 117-121.	1.1	2
381	Antithrombotic Therapy after Coronary-Artery Stenting. New England Journal of Medicine, 1999, 340, 1365-1368.	13.9	2
382	Synergism between factor XII ϵ 4C>T and factor XIII Val34Leu polymorphisms in fibrinolytic therapy in acute myocardial infarction. Thrombosis and Haemostasis, 2010, 104, 650-652.	1.8	2
383	Dexamethasone Induction of a Heat Stress Response. Methods in Enzymology, 2011, 490, 121-135.	0.4	2
384	Inherited thrombophilic conditions. Hematology, 2012, 17, s163-s166.	0.7	2
385	Compound heterozygosity involving Antithrombin Cambridge II (p.Ala416Ser) in antithrombin deficiency. Thrombosis and Haemostasis, 2013, 109, 556-558.	1.8	2
386	Preoperative Blood Ordering in Elective Colon Surgery: Requirement or Routine?. CirugÃa EspaÃ±ola (English Edition), 2014, 92, 44-51.	0.1	2
387	Evaluation of Novel Platelet Polymorphisms in Stroke. Dichotomic Effect of rs5443 in <i>GNB3</i> .		

#	ARTICLE	IF	CITATIONS
397	Detection of anomalies in cell-surface carbohydrates on thrombasthenic platelets using 125I-labeled lectins. <i>Blut</i> , 1986, 52, 91-97.	1.2	1
398	Letter to the editor: Hemostasis in malignancy. <i>American Journal of Hematology</i> , 1991, 38, 337-337.	2.0	1
399	ABO blood group does not increase the risk of thrombosis in Philadelphia-negative myeloproliferative disorders. <i>Blood Coagulation and Fibrinolysis</i> , 2009, 20, 390-392.	0.5	1
400	Measuring the prognostic impact of ferritin levels in myelodysplastic syndrome patients: the role of susceptibility biases. <i>Leukemia</i> , 2010, 24, 640-642.	3.3	1
401	C0229 Regulatory regions of SERPINC1 gene: Identification of the first mutation associated with antithrombin deficiency. <i>Thrombosis Research</i> , 2012, 130, S118.	0.8	1
402	Induced pluripotent stem cells derived from Bernard-Soulier Syndrome patient's peripheral blood cells with a p.Phe55Ser mutation in the GPIX gene. <i>Stem Cell Research</i> , 2017, 20, 10-13.	0.3	1
403	Anticoagulant therapy in patients with congenital FXI deficiency. <i>Blood Advances</i> , 2021, 5, 4083-4086.	2.5	1
404	Trasplante de progenitores hematopoyéticos de sangre periférica en España: análisis de coste. <i>Medicina Clínica</i> , 2004, 123, 401-405.	0.3	1
405	A common polymorphism in the annexin V Kozak sequence (A>T) increases translation efficiency and plasma levels of annexin V, and decreases the risk of myocardial infarction in young patients. <i>Blood</i> , 2002, 100, 2081-2086.	0.6	1
406	Detection of free hepatitis C virus core antigen by enzyme-linked immunosorbent assay is not suitable for screening of granulocyte colony-stimulating factor-mobilized hematopoietic progenitor donors. <i>Transfusion</i> , 2004, 44, 1755-1761.	0.8	0
407	C0094 High incidence of compound heterozygosity in antithrombin deficiency: Diagnostic and prognostic relevance. <i>Thrombosis Research</i> , 2012, 130, S117.	0.8	0
408	C0235 Identification of mutations in the protein C gene in a panel of 65 Spanish families with protein C deficiency. <i>Thrombosis Research</i> , 2012, 130, S110-S111.	0.8	0
409	C0075 Type II antithrombin deficiency caused by a large in-frame insertion. Structural, functional and pathological relevance. <i>Thrombosis Research</i> , 2012, 130, S116-S117.	0.8	0
410	Qué hacer ante una cirugía urgente en pacientes tratados con anticoagulantes orales de acción directa. <i>Angiología</i> , 2017, 69, 135-136.	0.0	0
411	Comparative assessment of prophylactic transfusions of platelet concentrates obtained by the PRP or buffy-coat methods, in patients undergoing allogeneic hematopoietic stem cell transplantation. <i>Hematology</i> , 2018, 23, 712-718.	0.7	0
412	Gynaecological and obstetrical bleeding in Caucasian women with congenital factor XI deficiency: Results from a twenty-year, retrospective, observational study. <i>Medicina Clínica (English Edition)</i> , 2019, 153, 373-379.	0.1	0
413	Guidelines of the Spanish ITP Group for the diagnosis, treatment and follow-up of patients with immune thrombocytopenia. <i>Medicina Clínica (English Edition)</i> , 2021, 157, 191-198.	0.1	0
414	Outpatient management of cancer-related pulmonary embolism: Analysis of 562 consecutive patients from the EPIPHANY study. <i>Journal of Clinical Oncology</i> , 2014, 32, 9526-9526.	0.8	0

#	ARTICLE	IF	CITATIONS
415	Anticipating High-Risk Chromosome Clonal Evolution in Chronic Lymphocytic Leukemia: A Next Generation Sequencing and Longitudinal FISH Combined Study. <i>Blood</i> , 2014, 124, 3305-3305.	0.6	0
416	Deubiquitinase BAP1 Downregulation in Myeloid Malignancies: A New Pathogenic Mechanism, Dominant in Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2014, 124, 5594-5594.	0.6	0
417	Abstract P5-09-06: Decrease of tumor F3 expression after neoadjuvant chemotherapy associates to lower survival in breast cancer. , 2015, , .		0
418	Persistent Cytotoxic T Lymphocyte Expansions after Allogeneic Hematopoietic Stem Cell Transplantation: Kinetics, Clinical Impact and Absence of STAT3 Mutations. <i>Blood</i> , 2015, 126, 3153-3153.	0.6	0
419	Metastatic breast cancer (MBC) patients's perspective in the valuation of health states for QALY calculation.. <i>Journal of Clinical Oncology</i> , 2016, 34, e18131-e18131.	0.8	0
420	Immunophenotypic Profile and Recurrent Somatic Mutations in 131 Chronic Lymphocytic Leukemia Patients: Low Expression of CD25 in NOTCH1-Mutated Cases. <i>Blood</i> , 2016, 128, 3201-3201.	0.6	0
421	Cambra system in patients awaiting hematopoietic progenitor cell transplant and high caries risk. <i>Journal of Clinical and Experimental Dentistry</i> , 2017, 9, 0-0.	0.5	0
422	Clinical Characteristics and Cardiovascular Events in Patients with Essential Thrombocythemia with $JAK2 V617F$ Allele Burden. <i>Blood</i> , 2019, 134, 4171-4171.	0.6	0
423	Respuesta. <i>Medicina Clínica</i> , 2021, 158, e2-e2.	0.3	0